Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.19310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug survival, effectiveness, and safety of guselkumab for moderate-to-severe psoriasis for up to 4 years.
Clin Exp Dermatol
January 2025
Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
Background: Guselkumab has been shown to be safe and effective for the treatment of psoriasis in numerous randomized clinical trials and real-life studies. Real life data on treatment up to 4 years are lacking.
Objectives: The present study aims to estimate the drug survival DS, effectiveness, and safety of guselkumab over a period of 208 weeks (w).
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience.
J Clin Med
August 2024
Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.
The term "super responder" identifies a group of patients who exhibit a rapid and optimal response to biological treatment compared to the overall treated population. The primary objective of our study is to characterize this subgroup of patients to enable the early identification of those who will respond most effectively to the proposed treatment while also evaluating clinical efficacy. This retrospective study evaluated 232 patients treated with guselkumab in monotherapy for at least 20 weeks between November 2018 and November 2023.
View Article and Find Full Text PDFNoninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
JAMA Dermatol
September 2024
Department of Dermatology, and Interdisciplinary Center for Inflammatory Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Importance: Psoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies.
Objective: To evaluate early intervention with and prolonging the dosing interval for guselkumab, a p19 subunit-targeted interleukin (IL)-23 inhibitor, in patients with moderate to severe psoriasis.
Design, Setting, And Participants: The GUIDE clinical trial is an ongoing phase 3b, randomized, double-blinded trial conducted across 80 centers in Germany and France comprising 3 parts evaluating the impact of early disease intervention, prolonged dosing interval, and maintenance of response following treatment withdrawal among adults with moderate to severe plaque psoriasis.
Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study.
J Clin Med
July 2024
Agrippa Ionescu Emergency Clinical Hospital, 011773 Bucharest, Romania.
: Psoriasis is an immune-mediated chronic disorder associated with various comorbidities. Even though biologics and small-molecule inhibitors are the mainstay treatment for moderate-to-severe psoriasis, there is no current consensus regarding which agent should be used for a specific type of patient. This paper aims to test the reliability of blood-count-derived inflammatory markers in assessing treatment response to biologics and small-molecule inhibitors in psoriasis.
View Article and Find Full Text PDFComparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year.
J Dermatolog Treat
December 2024
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Article Synopsis
- * Factors such as being female and having a lower Charlson Comorbidity Index are linked to a higher likelihood of being a super-responder, with high levels of HDL cholesterol associated with improved PASI scores.
- * Non-super-responders switching to IL-17A inhibitors also show potential for improvement, with around 35%-43% achieving a PASI 100 response, while all super-responders switching to IL-17A inhibitors achieved similar results much more quickly.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!